Alliancebernstein L.P. Beyond Spring Inc. Transaction History

Alliancebernstein L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $30,735 - $72,352	-27,200 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.68 - $5.01 $6,720 - $20,040	-4,000 Reduced 12.82%	27,200 $60,000
Q4 2021 Feb 14, 2022	SELL	$4.02 - $16.84 $11.8 Million - $49.3 Million	-2,926,528 Reduced 98.95%	31,200 $141,000
Q3 2021 Nov 10, 2021	SELL	$9.26 - $31.31 $468,000 - $1.58 Million	-50,540 Reduced 1.68%	2,957,728 $46.6 Million
Q2 2021 Jul 30, 2021	BUY	$9.37 - $12.12 $4.15 Million - $5.37 Million	443,045 Added 17.27%	3,008,268 $31.4 Million
Q1 2021 May 06, 2021	BUY	$10.61 - $15.77 $4.43 Million - $6.59 Million	417,821 Added 19.46%	2,565,223 $28.4 Million
Q4 2020 Feb 08, 2021	BUY	$10.21 - $17.31 $21.7 Million - $36.8 Million	2,125,102 Added 9529.61%	2,147,402 $26.2 Million
Q3 2020 Nov 12, 2020	BUY	$9.99 - $16.13 $10,989 - $17,743	1,100 Added 5.19%	22,300 $297,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $115,463 - $186,944	10,300 Added 94.5%	21,200 $320,000
Q1 2020 May 14, 2020	BUY	$9.68 - $18.47 $105,512 - $201,323	10,900 New	10,900 $140,000

5.77M

53.2K

2.5K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $91.5M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.